ripekg:evaluation/RIPEA4875E56C8C5C4ACF |
prov:used |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
rdfs:Resource |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
owl:Thing |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
ripe:RegistryEvidenceRegistry evidence |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
rdf:type |
tido:Evidence |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
prov:wasAttributedTo |
ripekg:source/clinicaltrials-govClinicalTrials.gov |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA4875E56C8C5C4ACF |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA4875E56C8C5C4ACF |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
ripe:concerns |
ripekg:work/10.1136%2Fannrheumdis-2014-205698Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
ripe:registrationAssessmentRationale |
LLM-extracted recruitment start date (normalized_date) is missing or empty. |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
ripe:registrationDate |
01-10-2008 |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
ripe:registrationId |
NCT00764725 |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
ripe:registrationLink |
https://clinicaltrials.gov/study/NCT00764725 |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
ripe:registryName |
ClinicalTrials.gov |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA4875E56C8C5C4ACF-human-2-2 |
ripekg:registry-evidence/RIPEA4875E56C8C5C4ACF |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA4875E56C8C5C4ACF-inspectai-2-2 |